Atlas Trials

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

Clinical trial NCT01615029 · COMPLETED

Trial details

NCT number
NCT01615029
Sponsor
Janssen Research & Development, LLC
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2012-06-26
Primary completion
2015-10-02
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.